Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents.
Although conventional multimodality approaches allowed improvement in the prognosis of patients with cervix cancer, several tumors do not respond similarly to standard approaches. Recent advances in basic research and genomics have improved our understanding of the biologic basis of the tumor development and progression. Tumor profiling allows for more selective therapeutic strategies leading to the identification of biomarkers or indicators of treatment response and to increased clinical efficacy through development of targeted therapies. Several markers have been identified, that are involved in cellular proliferation, interaction with angiogenesis, extracellular matrice adhesion/invasion, apoptosis, cell cycle pathways and DNA repair mechanisms. In this report, molecular profiling of uterine cervix carcinoma were reviewed with a special focus on rationally designed target-based anticancer agents, in order to clarify and to summary the present state of art in these particular promising area in cervix cancer management.
Magné
Nicolas
N
Department of Radiotherapy, Institut Gustave-Roussy, Villejuif, France. nicolas.magne@igr.fr
Chargari
Cyrus
C
Deutsch
Eric
E
Castadot
Pierre
P
Ghalibafian
Mitra
M
Bourhis
Jean
J
Haie-Meder
Christine
C
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor